CRBP Live signaler | Maksimer profitt med Getagraph.com

SELG 107800 min ago

@ $23.69

Utstedt: 14 feb 2024 @ 15:41

Avkastning: 44.58%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: 11.15 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases...

Stats
Dagens volum	96 876.00
Gjennomsnittsvolum	404 033
Markedsverdi	359.39M
EPS	$0 ( 2024-03-12 )
Neste inntjeningsdato	( $-1.090 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.32
ATR14	$0.107 (0.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Moran Sean F.	Buy	1 787	Common Stock
2024-04-10	Moran Sean F.	Sell	1 787	Employee Stock Option (right to buy)
2024-03-08	Cormorant Asset Management, Lp	Buy	8 862	Common Stock
2024-03-08	Cormorant Asset Management, Lp	Buy	156 597	Common Stock
2024-03-08	Cormorant Asset Management, Lp	Buy	61 668	Common Stock

INSIDER POWER
99.57
Last 95 transactions
Buy: 14 080 389 \| Sell: 365 661

Volum Korrelasjon

Lang: -0.13 (neutral)

Kort: -0.68 (moderate negative)

Signal:(47.691) Neutral

Corbus Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
VKTX	0.923
BLPH	0.919
CHMA	0.904
BTF	0.903
ALBO	0.902
SUMO	0.901
CMPI	0.901
NVCN	0.899
IMRX	0.885
NLTX	0.885

10 Mest negative korrelasjoner
MSBI	-0.949
BWFG	-0.948
NFBK	-0.946
CNOB	-0.944
ONB	-0.944
PFBC	-0.944
FBIZ	-0.943
PGC	-0.943
BCBP	-0.941
WSFS	-0.941

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Corbus Pharmaceuticals Korrelasjon - Valuta/Råvare

-0.34
( neutral )

-0.28
( neutral )

0.59
( weak )

0.25
( neutral )

0.49
( neutral )

0.46
( neutral )

Corbus Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-641 000 (0.00 %)
EPS:	$-10.31

FY	2023
Omsetning:	$0
Bruttogevinst:	$-641 000 (0.00 %)
EPS:	$-10.31

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.49M (0.00 %)
EPS:	$-13.39

FY	2021
Omsetning:	$881 705
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.